CXCR4 and neoplasm: We here aimed to evaluate (i) the subtumor distribution of CXCR4 in human clinical specimens of OSCC and (ii) the effects of a CXCR4 antagonist AMD3100, so-called plerixafor, on inhibition of tumor angiogenesis and tumor growth in mice xenografted with OSCC cells.